Godavari Biorefineries (GODAVARIB) — Announcement

📢 Key Event
EPO grants patent for anti-cancer composition

Godavari Biorefineries announced that the European Patent Office granted a patent for its novel anti-cancer pharmaceutical composition and preparation process, strengthening its oncology IP portfolio and potentially expanding therapeutic options for breast and prostate cancer treatment.

📄 View Original Announcement (PDF)

📊 Stock Analysis — GODAVARIB ✨ Ask AI About This

About Godavari Biorefineries Limited (GODAVARIB)

Fast Moving Consumer Goods · Diversified FMCG · Listed on NSE

Market Cap: ₹1,527.86 Cr P/E: 67.7

View full GODAVARIB stock details →

📡 Get AI alerts when GODAVARIB files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GODAVARIB — Free

💡 Ask AI about this filing

"How will this patent impact future revenue streams?" "What cancer indications are targeted by this composition?" "When might commercialization of this therapy begin?"

Ask AI Free →

📊 More GODAVARIB filings

See all GODAVARIB filings →

🔥 Also filed on 11 August 2026

ULTRACEMCO UltraTech Cement Limited Announcement SUDEEPPHRM Sudeep Pharma Limited Financial Results SUTLEJTEX Sutlej Textiles and Industries Limited Financial Results RBZJEWEL RBZ Jewellers Limited Financial Results TATVA Tatva Chintan Pharma Chem Limited Corporate Action AETHER Aether Industries Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GODAVARIB files new disclosures

Track GODAVARIB filings, board meetings, and corporate actions. Free email alerts at 5 PM.